Shockwave Medical is developing the Lithoplasty family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.
San Francisco Bay Area companies raise so much venture capital relative to other places that a lot of little-known cities in the region outrank major metropolises in total funding. In this two-part series, we’ll look at nine under-the-radar places in the Bay Area that punch above their weight class…
Equity funding and deals to private medical device companies ticked up in 2016 following a downturn in 2015. Meanwhile, concerns over medical device cybersecurity risks continued to make headlines in the second half of the year, bringing increased uncertainty to … Continued
Medical device funding is on track to reach $3.5B in 2016, a slight increase over last year’s dollar total. Since 2012, most funding to medical device startups has occurred in the United States, with NEA leading venture capital activity and Johnson & … Continued